glp 1 testosterone Effect of GLP-1 agonists on levels: a systematic review and meta-analysis MSN

In a recent phase II trial with subcutaneous semaglutide, when doses were escalated relatively rapidly to 16 mg weekly, participants experienced additional weight loss, but at the expense of more adverse effects (21)

What was once a relatively small class of drugs has become one of the most significant drivers of pharmacy spend, transforming diabetes care and offering new treatment options to help address obesity

Stated differently, FM loss occurred at a rate 2-3x higher than FFM loss

Cardiovasc Drugs Ther (2019) 33(6):6617

Off-Label Use: When a medication FDA-approved for one condition (like diabetes) is prescribed for a different condition (like weight loss)

The market is expected to climb to US$ 211.8 Bn by 2035